Analytical Performance of the EasyPGX Ready NTRK Fusion Assay for Detecting Tumor-Agnostic NTRK Gene Fusions in Solid Tumors
- 1Gerhard-Domagk-Institute of Pathology, University Hospital Münster, Domagkstr. 17, 48149 Münster, Germany
- 2West German Cancer Center, University Hospital Münster, 48167 Münster, Germany
Abstract
Early detection and accurate characterization of pathogenic NTRK1, NTRK2, and NTRK3 gene rearrangements have become essential components of multimodal testing frameworks to select gene fusion-positive candidates for NTRK-directed molecularly targeted therapies. This retrospective study presents the first independent validation of the CE-IVD-compliant EasyPGX ready NTRK Fusion assay, a ready-to-use RT-PCR workflow for the qualitative detection of NTRK1,2,3 gene fusions in solid tumors. Based on the fusion frequency in our institutional pathology cohort, the potential diagnostic coverage of the streamlined fast-track assay was 93.8% (15/16) for NTRK1, 100% (1/1) for NTRK2, and 58.8% (10/17) for NTRK3 rearrangement, including TPM3, LMNA, TPR, STRN, and ETV6 as 5′ fusion partners. Twenty-nine archived FFPE tumor specimens with known NTRK1,2,3 gene rearrangement status, and two multiplexed FFPE NTRK fusion reference standards were tested. Targeted RNA-based next-generation sequencing served as the diagnostic benchmark reference method. Conclusive results were obtained for all 31 RNA samples, including FFPE tumor specimens archived for up to six years. The observed overall sensitivity was 96% (23/24; 95% CI, 78.9–99.9%) and no false-positive results were observed for any of the nine gene fusion targets (observed specificity 100%); the single discordant result occurred in a fusion-positive sample with borderline transcript abundance at the lower limit of the assay’s dynamic range. Dilution experiments indicated valid detection at 6.25 ng RNA input per reaction for all fusion transcripts tested, with robust inter-run repeatability and no false-positive results. In this single-center study, the CE-IVD-compliant EasyPGX ready NTRK Fusion assay demonstrated analytical performance within its predefined repertoire of NTRK1,2,3 rearrangements, consistent with guideline thresholds, supporting its potential as a first-level fast-track component of multimodal pan-cancer diagnostic workflows.
Related
- Analytical and Biological Factors Associated with Oncogenic Variant Yield in Tumor-Agnostic Plasma ctDNA Profiling
- Total wrist fusions alter scapular kinematics during functional task performance.
- Diagnostic Performance of Clinical Examination for Detecting Knee Effusion: Impact of Obesity and Periarticular Adiposity
- Diagnostic Performance of Color Doppler Ultrasound for Detecting Nuchal Cord and Associated Immediate Neonatal Outcomes at Term in Uganda: A Prospective Diagnostic‐Accuracy Cohort Study
- Diagnostic Performance of a Deep Learning Model Using Phonocardiogram and Single‐Lead ECG Signals for Detecting Moderate‐or‐Greater Aortic Stenosis: Multicenter External Validation
BibTeX
@article{soiron2026analytical,
title = {{Analytical Performance of the EasyPGX Ready NTRK Fusion Assay for Detecting Tumor-Agnostic NTRK Gene Fusions in Solid Tumors}},
author = {Anna Soiron and Kim Falkenberg and Santina Kirmse and Laura Braun and Elias Dohmen and Daniel Kaschta and Ilka Isfort and Ruth Berthold and Anne Offermann and Eva Wardelmann and Wolfgang Hartmann and Marcel Trautmann},
journal = {Cells},
year = {2026},
month = oct,
doi = {10.3390/cells15201833},
url = {https://www.mdpi.com/2073-4409/15/20/1833},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Analytical Performance of the EasyPGX Ready NTRK Fusion Assay for Detecting Tumor-Agnostic NTRK Gene Fusions in Solid Tumors
AU - Anna Soiron
AU - Kim Falkenberg
AU - Santina Kirmse
AU - Laura Braun
AU - Elias Dohmen
AU - Daniel Kaschta
AU - Ilka Isfort
AU - Ruth Berthold
AU - Anne Offermann
AU - Eva Wardelmann
AU - Wolfgang Hartmann
AU - Marcel Trautmann
PY - 2026
DA - 2026/10/09
JO - Cells
DO - 10.3390/cells15201833
UR - https://www.mdpi.com/2073-4409/15/20/1833
AB - Early detection and accurate characterization of pathogenic NTRK1, NTRK2, and NTRK3 gene rearrangements have become essential components of multimodal testing frameworks to select gene fusion-positive candidates for NTRK-directed molecularly targeted therapies. This retrospective study presents the first independent validation of the CE-IVD-compliant EasyPGX ready NTRK Fusion assay, a ready-to-use RT-PCR workflow for the qualitative detection of NTRK1,2,3 gene fusions in solid tumors. Based on the fusion frequency in our institutional pathology cohort, the potential diagnostic coverage of the streamlined fast-track assay was 93.8% (15/16) for NTRK1, 100% (1/1) for NTRK2, and 58.8% (10/17) for NTRK3 rearrangement, including TPM3, LMNA, TPR, STRN, and ETV6 as 5′ fusion partners. Twenty-nine archived FFPE tumor specimens with known NTRK1,2,3 gene rearrangement status, and two multiplexed FFPE NTRK fusion reference standards were tested. Targeted RNA-based next-generation sequencing served as the diagnostic benchmark reference method. Conclusive results were obtained for all 31 RNA samples, including FFPE tumor specimens archived for up to six years. The observed overall sensitivity was 96% (23/24; 95% CI, 78.9–99.9%) and no false-positive results were observed for any of the nine gene fusion targets (observed specificity 100%); the single discordant result occurred in a fusion-positive sample with borderline transcript abundance at the lower limit of the assay’s dynamic range. Dilution experiments indicated valid detection at 6.25 ng RNA input per reaction for all fusion transcripts tested, with robust inter-run repeatability and no false-positive results. In this single-center study, the CE-IVD-compliant EasyPGX ready NTRK Fusion assay demonstrated analytical performance within its predefined repertoire of NTRK1,2,3 rearrangements, consistent with guideline thresholds, supporting its potential as a first-level fast-track component of multimodal pan-cancer diagnostic workflows.
SN - 2073-4409
ER -